GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults
Osteoprotegerin (OPG), a glycoprotein belonging to the tumor necrosis factor receptor family, is an endogenous inhibitor of osteoclastogenesis produced by cells of the osteoblast lineage. OPG is a key cytokine involved in the regulation of osteoblast/osteoclast cross-talk. Since GH replacement thera...
Gespeichert in:
| Veröffentlicht in: | European journal of endocrinology 2003-02, Vol.148 (2), p.185-191 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 191 |
|---|---|
| container_issue | 2 |
| container_start_page | 185 |
| container_title | European journal of endocrinology |
| container_volume | 148 |
| creator | LANZI, Roberto LOSA, Marco VILLA, Isabella GATTI, Elisa SIRTORI, Marcella DAL FIUME, Chiara RUBINACCI, Alessandro |
| description | Osteoprotegerin (OPG), a glycoprotein belonging to the tumor necrosis factor receptor family, is an endogenous inhibitor of osteoclastogenesis produced by cells of the osteoblast lineage. OPG is a key cytokine involved in the regulation of osteoblast/osteoclast cross-talk. Since GH replacement therapy in GH deficiency (GHD) activates bone remodeling and increases bone mass, we investigated if short-term GH replacement therapy affects plasma OPG levels.
Eighteen adults with GHD, ranging from 17 to 51 Years (nine childhood-onset and nine adult-onset) were enrolled in the study. All subjects were on stable replacement therapy, especially sex hormones. The starting dose of GH replacement therapy was 4 microg/kg per day x 7 days/week, and was progressively increased according to the serum IGF-I values. Biochemical parameters of bone and mineral metabolism were measured before and after 6 Months of GH replacement therapy. Bone mass density (BMD) was monitored at three skeletal sites (lumbar vertebrae, femur, radius) by dual-energy X-ray absorptiometry.
After 6 Months of therapy, ionized calcium, parathyroid hormone and 25-OH vitamin D did not change, whereas total serum calcium and urinary calcium excretion increased significantly (P |
| doi_str_mv | 10.1530/eje.0.1480185 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73038651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73038651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-d9f3df77c1f5210e725c2fa319fb5c70f954c3531a5ddd944c2726c44ee9055d3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlaPXmUvetuabJLN7lGKtkLBiwVvS5pMdEv2w8yu0H9vSgs9zQvzzMvwEHLP6JxJTp9hB_MYRUFZIS_IlAlVpnnBvy7JlBZUpCIXfEJuEHeUspjpNZmwTJY052pKNstVEqD32kAD7ZAMPxB0v0_q1gTQCJjEHTY66XCArg_dAN8Q6jbx8AceI5csV6kFV5v6cK_t6Ae8JVdOe4S705yRzdvr52KVrj-W74uXdWp4oYbUlo5bp5RhTmaMgsqkyZzmrHRbaRR1pRSGS860tNaWQphMZbkRAqCkUlo-I0_H3vjY7wg4VE2NBrzXLXQjVopTXuSSRTA9giZ0iAFc1Ye60WFfMVodPFbRYxXj0WPkH07F47YBe6ZP4iLweAI0Gu1d0K2p8cwJGU3zjP8DsWN71w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73038651</pqid></control><display><type>article</type><title>GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>LANZI, Roberto ; LOSA, Marco ; VILLA, Isabella ; GATTI, Elisa ; SIRTORI, Marcella ; DAL FIUME, Chiara ; RUBINACCI, Alessandro</creator><creatorcontrib>LANZI, Roberto ; LOSA, Marco ; VILLA, Isabella ; GATTI, Elisa ; SIRTORI, Marcella ; DAL FIUME, Chiara ; RUBINACCI, Alessandro</creatorcontrib><description>Osteoprotegerin (OPG), a glycoprotein belonging to the tumor necrosis factor receptor family, is an endogenous inhibitor of osteoclastogenesis produced by cells of the osteoblast lineage. OPG is a key cytokine involved in the regulation of osteoblast/osteoclast cross-talk. Since GH replacement therapy in GH deficiency (GHD) activates bone remodeling and increases bone mass, we investigated if short-term GH replacement therapy affects plasma OPG levels.
Eighteen adults with GHD, ranging from 17 to 51 Years (nine childhood-onset and nine adult-onset) were enrolled in the study. All subjects were on stable replacement therapy, especially sex hormones. The starting dose of GH replacement therapy was 4 microg/kg per day x 7 days/week, and was progressively increased according to the serum IGF-I values. Biochemical parameters of bone and mineral metabolism were measured before and after 6 Months of GH replacement therapy. Bone mass density (BMD) was monitored at three skeletal sites (lumbar vertebrae, femur, radius) by dual-energy X-ray absorptiometry.
After 6 Months of therapy, ionized calcium, parathyroid hormone and 25-OH vitamin D did not change, whereas total serum calcium and urinary calcium excretion increased significantly (P<0.01). Also osteocalcin and urinary deoxypyridinoline/24 h increased significantly (P<0.02, P<0.05 respectively). Mean basal T-scores of BMD values showed an osteopenic state, which remained unchanged after GH therapy. Plasma OPG increased significantly after 6 Months of therapy (P<0.02) and this increase was significantly correlated with the increase of osteocalcin (r=-0.52; P=0.04) and deoxypyridinoline values (r=-0.64; P=0.011).
Our results suggest that the bone anabolic effect of GH replacement therapy could in part be mediated by a positive bone balance at each remodeling unit due to the inhibitory action of OPG on osteoclastogenesis.</description><identifier>ISSN: 0804-4643</identifier><identifier>EISSN: 1479-683X</identifier><identifier>DOI: 10.1530/eje.0.1480185</identifier><identifier>PMID: 12590637</identifier><language>eng</language><publisher>Colchester: Portland Press</publisher><subject>Adolescent ; Adult ; Amino Acids - urine ; Biological and medical sciences ; Calcium - blood ; Calcium - urine ; Endocrinopathies ; Female ; Glycoproteins - blood ; Growth Hormone - therapeutic use ; Hormones. Endocrine system ; Human Growth Hormone - deficiency ; Humans ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Male ; Medical sciences ; Middle Aged ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Osteocalcin - blood ; Osteoprotegerin ; Pharmacology. Drug treatments ; Receptors, Cytoplasmic and Nuclear - blood ; Receptors, Tumor Necrosis Factor</subject><ispartof>European journal of endocrinology, 2003-02, Vol.148 (2), p.185-191</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-d9f3df77c1f5210e725c2fa319fb5c70f954c3531a5ddd944c2726c44ee9055d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14543032$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12590637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LANZI, Roberto</creatorcontrib><creatorcontrib>LOSA, Marco</creatorcontrib><creatorcontrib>VILLA, Isabella</creatorcontrib><creatorcontrib>GATTI, Elisa</creatorcontrib><creatorcontrib>SIRTORI, Marcella</creatorcontrib><creatorcontrib>DAL FIUME, Chiara</creatorcontrib><creatorcontrib>RUBINACCI, Alessandro</creatorcontrib><title>GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults</title><title>European journal of endocrinology</title><addtitle>Eur J Endocrinol</addtitle><description>Osteoprotegerin (OPG), a glycoprotein belonging to the tumor necrosis factor receptor family, is an endogenous inhibitor of osteoclastogenesis produced by cells of the osteoblast lineage. OPG is a key cytokine involved in the regulation of osteoblast/osteoclast cross-talk. Since GH replacement therapy in GH deficiency (GHD) activates bone remodeling and increases bone mass, we investigated if short-term GH replacement therapy affects plasma OPG levels.
Eighteen adults with GHD, ranging from 17 to 51 Years (nine childhood-onset and nine adult-onset) were enrolled in the study. All subjects were on stable replacement therapy, especially sex hormones. The starting dose of GH replacement therapy was 4 microg/kg per day x 7 days/week, and was progressively increased according to the serum IGF-I values. Biochemical parameters of bone and mineral metabolism were measured before and after 6 Months of GH replacement therapy. Bone mass density (BMD) was monitored at three skeletal sites (lumbar vertebrae, femur, radius) by dual-energy X-ray absorptiometry.
After 6 Months of therapy, ionized calcium, parathyroid hormone and 25-OH vitamin D did not change, whereas total serum calcium and urinary calcium excretion increased significantly (P<0.01). Also osteocalcin and urinary deoxypyridinoline/24 h increased significantly (P<0.02, P<0.05 respectively). Mean basal T-scores of BMD values showed an osteopenic state, which remained unchanged after GH therapy. Plasma OPG increased significantly after 6 Months of therapy (P<0.02) and this increase was significantly correlated with the increase of osteocalcin (r=-0.52; P=0.04) and deoxypyridinoline values (r=-0.64; P=0.011).
Our results suggest that the bone anabolic effect of GH replacement therapy could in part be mediated by a positive bone balance at each remodeling unit due to the inhibitory action of OPG on osteoclastogenesis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Amino Acids - urine</subject><subject>Biological and medical sciences</subject><subject>Calcium - blood</subject><subject>Calcium - urine</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Glycoproteins - blood</subject><subject>Growth Hormone - therapeutic use</subject><subject>Hormones. Endocrine system</subject><subject>Human Growth Hormone - deficiency</subject><subject>Humans</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Osteocalcin - blood</subject><subject>Osteoprotegerin</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Cytoplasmic and Nuclear - blood</subject><subject>Receptors, Tumor Necrosis Factor</subject><issn>0804-4643</issn><issn>1479-683X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMotlaPXmUvetuabJLN7lGKtkLBiwVvS5pMdEv2w8yu0H9vSgs9zQvzzMvwEHLP6JxJTp9hB_MYRUFZIS_IlAlVpnnBvy7JlBZUpCIXfEJuEHeUspjpNZmwTJY052pKNstVEqD32kAD7ZAMPxB0v0_q1gTQCJjEHTY66XCArg_dAN8Q6jbx8AceI5csV6kFV5v6cK_t6Ae8JVdOe4S705yRzdvr52KVrj-W74uXdWp4oYbUlo5bp5RhTmaMgsqkyZzmrHRbaRR1pRSGS860tNaWQphMZbkRAqCkUlo-I0_H3vjY7wg4VE2NBrzXLXQjVopTXuSSRTA9giZ0iAFc1Ye60WFfMVodPFbRYxXj0WPkH07F47YBe6ZP4iLweAI0Gu1d0K2p8cwJGU3zjP8DsWN71w</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>LANZI, Roberto</creator><creator>LOSA, Marco</creator><creator>VILLA, Isabella</creator><creator>GATTI, Elisa</creator><creator>SIRTORI, Marcella</creator><creator>DAL FIUME, Chiara</creator><creator>RUBINACCI, Alessandro</creator><general>Portland Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults</title><author>LANZI, Roberto ; LOSA, Marco ; VILLA, Isabella ; GATTI, Elisa ; SIRTORI, Marcella ; DAL FIUME, Chiara ; RUBINACCI, Alessandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-d9f3df77c1f5210e725c2fa319fb5c70f954c3531a5ddd944c2726c44ee9055d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Amino Acids - urine</topic><topic>Biological and medical sciences</topic><topic>Calcium - blood</topic><topic>Calcium - urine</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Glycoproteins - blood</topic><topic>Growth Hormone - therapeutic use</topic><topic>Hormones. Endocrine system</topic><topic>Human Growth Hormone - deficiency</topic><topic>Humans</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Osteocalcin - blood</topic><topic>Osteoprotegerin</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Cytoplasmic and Nuclear - blood</topic><topic>Receptors, Tumor Necrosis Factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LANZI, Roberto</creatorcontrib><creatorcontrib>LOSA, Marco</creatorcontrib><creatorcontrib>VILLA, Isabella</creatorcontrib><creatorcontrib>GATTI, Elisa</creatorcontrib><creatorcontrib>SIRTORI, Marcella</creatorcontrib><creatorcontrib>DAL FIUME, Chiara</creatorcontrib><creatorcontrib>RUBINACCI, Alessandro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LANZI, Roberto</au><au>LOSA, Marco</au><au>VILLA, Isabella</au><au>GATTI, Elisa</au><au>SIRTORI, Marcella</au><au>DAL FIUME, Chiara</au><au>RUBINACCI, Alessandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults</atitle><jtitle>European journal of endocrinology</jtitle><addtitle>Eur J Endocrinol</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>148</volume><issue>2</issue><spage>185</spage><epage>191</epage><pages>185-191</pages><issn>0804-4643</issn><eissn>1479-683X</eissn><abstract>Osteoprotegerin (OPG), a glycoprotein belonging to the tumor necrosis factor receptor family, is an endogenous inhibitor of osteoclastogenesis produced by cells of the osteoblast lineage. OPG is a key cytokine involved in the regulation of osteoblast/osteoclast cross-talk. Since GH replacement therapy in GH deficiency (GHD) activates bone remodeling and increases bone mass, we investigated if short-term GH replacement therapy affects plasma OPG levels.
Eighteen adults with GHD, ranging from 17 to 51 Years (nine childhood-onset and nine adult-onset) were enrolled in the study. All subjects were on stable replacement therapy, especially sex hormones. The starting dose of GH replacement therapy was 4 microg/kg per day x 7 days/week, and was progressively increased according to the serum IGF-I values. Biochemical parameters of bone and mineral metabolism were measured before and after 6 Months of GH replacement therapy. Bone mass density (BMD) was monitored at three skeletal sites (lumbar vertebrae, femur, radius) by dual-energy X-ray absorptiometry.
After 6 Months of therapy, ionized calcium, parathyroid hormone and 25-OH vitamin D did not change, whereas total serum calcium and urinary calcium excretion increased significantly (P<0.01). Also osteocalcin and urinary deoxypyridinoline/24 h increased significantly (P<0.02, P<0.05 respectively). Mean basal T-scores of BMD values showed an osteopenic state, which remained unchanged after GH therapy. Plasma OPG increased significantly after 6 Months of therapy (P<0.02) and this increase was significantly correlated with the increase of osteocalcin (r=-0.52; P=0.04) and deoxypyridinoline values (r=-0.64; P=0.011).
Our results suggest that the bone anabolic effect of GH replacement therapy could in part be mediated by a positive bone balance at each remodeling unit due to the inhibitory action of OPG on osteoclastogenesis.</abstract><cop>Colchester</cop><pub>Portland Press</pub><pmid>12590637</pmid><doi>10.1530/eje.0.1480185</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0804-4643 |
| ispartof | European journal of endocrinology, 2003-02, Vol.148 (2), p.185-191 |
| issn | 0804-4643 1479-683X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73038651 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adolescent Adult Amino Acids - urine Biological and medical sciences Calcium - blood Calcium - urine Endocrinopathies Female Glycoproteins - blood Growth Hormone - therapeutic use Hormones. Endocrine system Human Growth Hormone - deficiency Humans Hypothalamus. Hypophysis. Epiphysis (diseases) Male Medical sciences Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Osteocalcin - blood Osteoprotegerin Pharmacology. Drug treatments Receptors, Cytoplasmic and Nuclear - blood Receptors, Tumor Necrosis Factor |
| title | GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A49%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GH%20replacement%20therapy%20increases%20plasma%20osteoprotegerin%20levels%20in%20GH-deficient%20adults&rft.jtitle=European%20journal%20of%20endocrinology&rft.au=LANZI,%20Roberto&rft.date=2003-02-01&rft.volume=148&rft.issue=2&rft.spage=185&rft.epage=191&rft.pages=185-191&rft.issn=0804-4643&rft.eissn=1479-683X&rft_id=info:doi/10.1530/eje.0.1480185&rft_dat=%3Cproquest_cross%3E73038651%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73038651&rft_id=info:pmid/12590637&rfr_iscdi=true |